DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cysteamine
Cysteamine
Cystinosis
Horizon Therapeutics Public Annual Report 2020
Primechoice Accord Formulary, January 2019 I 2018
New Drug Approvals and Extended Indications for Infants, Children, and Adolescents Marcia L
Specialty Pharmacy Program Drug List
Cysteamine: an Old Drug with New Potential
Annual Report 2018
Cysteine, Glutathione, and Thiol Redox Balance in Astrocytes
Israel Atomic Energy Commission • \ IA-1404
Cysteamine-Containing Products Policy #: Rx.01.136
[Poster Title]
A European Specialty Pharmaceutical Group COMPANY PROFILE and STRATEGY
Appraisal of NICE's Cost-Effectiveness Thresholds for Assessing Orphan
Lists of Medicinal Products for Rare Diseases in Europe*
Cysteamine Toxicity in Patients with Cystinosis
May2013 CPG Updates
Cysteamine-Bicalutamide Combination Treatment Restores Alpha-Ketoglutarate and Corrects Proximal Tubule Phenotype in Cystinosis
Pantethine and Cystamine Deplete Cystine from Cystinotic Fibroblasts Via Efflux of Cysteamine-Cysteine Mixed Disulfide
Top View
Horizon Pharma Public Limited Company 2016 Annual Report
Availability, Accessibility and Delivery to Patients of the 28 Orphan
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Print Annual Reviews for Fiscal Year 2018
Thiol Dioxygenases: an Investigation Into the Mechanisms Of
Serve You Rx Prior Authorization Information and Drug List
FDA Orphan Drug Designations for Lysosomal Storage Disorders – A
The Spectrum of Mutations of Homocystinuria in the MENA Region
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
Glycerol Phenylbutyrate
Self-Administered Specialty Drug List
Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease
Challenges for Cysteamine Stabilization, Quantification, and Biological Effects Improvement Carla Atallah, Catherine Charcosset, Hélène Greige-Gerges
Specialty Formulary
Pharmacy Specialty Drug Policies
Specialty Pharmacy Program Drug List
Premium Value
Rare Disease Treatment Resource Guide
Supplemental Information
Us 2008/0085251 A1 M
Past Vs. Present New Generation of Specialty Management
Cystinosis and Its Treatment
Muscle Carnitine Repletion by Long-Term Carnitine Supplementation in Nephropathic Cystinosis
New Brunswick Drug Plans Formulary
KDIGO Controversies Conference on Nephropathic Cystinosis Breakout
PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules) Label
Different Inhibition Characteristics of Intracellular Transglutaminase Activity by Cystamine and Cysteamine
Orange Book Cumulative Supplement 7 July 2021
Oral Carnitine Therapy in Children with Cystinosis and Renal Fanconi Syndrome
Cystadrops 3769
Specialty Pipeline Update
Change to the Highmark Health Services Drug
The Abcs of Regulatory Science
Quantity Limits — Select
Drugs for Rare Diseases
Procysbi 2465
AHFS Pharmacologic-Therapeutic Classification System
11 Pdf [488 K]
Medimpact April 2019 Specialty Drug List
Prior Authorization — Premium
Paragraph IV Patent Certifications (PPIV)
Evolvement of EU Regulations on Innovative Medicines’ Was Accepted for Poster Presentation at the 77Th International Pharmaceutical Federation
A European Specialty Pharmaceutical Group
Inherited Metabolic Diseases (IMD) Program List of Disorders, Covered Drugs, Supplements and Specialty Foods
Procysbi Cystagon (Cysteamine Bitartrate) Prior Authorization Criteria
Utah Medicaid Dur Report December 2017 Overview Of
Appendix 1 Evaluation of the Serum Metabolome of Patients with Alkaptonuria After 2 Years of Treatment with Nitisinone Using 1D Proton
Pantetheinase Activity and Cysteamine Content in Cystinotic and Normal Fibroblasts and Leukocytes
Current Strategies for the Biochemical Diagnosis and Monitoring of Mitochondrial Disease
November 2020
Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
Cysteamine Bitartrate) Capsules 50 Mg and 150 Mg
List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic To
Carbon-Fluorine Bond Cleavage Mediated by Metalloenzymes
Therapies for Two Rare Diseases ICORD